Cambridge, USA-based generative protein design pioneer Nabla Biotoday announced a new, multi-year research collaboration with Japanese pharma major Takeda (TYO: 4502).

Under the terms of the agreement, Nabla Bio will receive double-digit millions in upfront and research cost payments and is eligible to receive success-based payments that may exceed $1 billion in total.

The Massachusetts-based biotech raised a $26 million Series A last year to integrate AI and wet lab technologies to precisely design drugs, including antibodies that target multipass membrane proteins, such as G protein-coupled receptors (GPCRs), ion channels and transporters.